文献速递妇科

妇科恶性肿瘤盆腔廓清术的实施与结局:一项基于人群的研究

Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study.
PubMed 文献 · Gynecol Oncol · 2019-02-19

该研究基于2001至2015年全国住院患者样本,回顾性分析了2647例因妇科恶性肿瘤行盆腔廓清术的患者。结果显示患者肥胖和合并症显著增加,围手术期并发症率68.1%,死亡率1.9%,住院时间和费用显著上升。

要点

  • 宫颈癌最常见(45.1%),阴道癌次之(27.6%)。
  • Charlson合并症指数≥3者从23.3%增至33.3%,肥胖者从4.5%增至19.4%。
  • 围手术期并发症率68.1%,死亡率1.9%,中位住院14天,费用显著增加。

核心结论

  • 研究期间接受盆腔廓清术的妇科恶性肿瘤患者肥胖和合并症增加。
  • 盆腔廓清术与高发病率、高死亡率及大量治疗相关费用相关。

研究设计与样本

  • 基于人群的回顾性研究,使用2001至2015年全国住院患者样本。
  • 纳入2647例因宫颈、子宫、阴道和外阴恶性肿瘤行盆腔廓清术的女性。

主要发现

  • 宫颈癌最常见(45.1%),阴道癌27.6%。
  • Charlson合并症指数≥3者从2001-2005年的23.3%增至2011-2015年的33.3%(相对增加42.9%,P<0.001)。
  • 肥胖女性从2001-2005年的4.5%增至2011-2015年的19.4%(相对增加3.3倍,P<0.001)。
  • 围手术期并发症率68.1%,其中38.7%有多种并发症;死亡率1.9%。
  • 多种围手术期并发症者从2001-2005年的29.4%增至2011-2015年的52.8%(相对增加78.6%,P<0.001)。

关键数值与推荐

  • 多因素分析显示,较近的手术年份、肥胖、较高合并症、较高家庭收入、在大床位医院手术、尿流改道、阴道重建和外阴癌与多种并发症风险增加相关(均P<0.05)。
  • 中位住院时间14天(IQR 9-21),住院≥28天者从2001-2005年的12.6%增至2011-2015年的19.1%(相对增加51.6%,P<0.001)。
  • 2001至2015年间,中位校正总费用从121,854美元增至185,100美元(净差+63,246美元,相对增加51.9%,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine changes in performance and outcomes of pelvic exenteration for gynecologic malignancies. METHODS: This is a population-based retrospective study examining the Nationwide Inpatient Sample between 2001 and 2015. Women with cervical, uterine, vaginal, and vulvar malignancies who underwent pelvic exenteration were examined. Comorbidity, perioperative complications, total charges, length of stay, and mortality were assessed. RESULTS: There were 2647 cases included. Cervical cancer was the most common malignancy (45.1%), followed by vaginal cancer (27.6%). 26.9% of women had a Charlson Comorbidity Index ≥3, which significantly increased from 23.3% in 2001-2005 to 33.3% in 2011-2015 (42.9% relative increase, P < 0.001). Obese women undergoing exenteration increased significantly from 4.5% in 2001-2005 to 19.4% in 2011-2015 (3.3-fold relative increase, P < 0.001). The perioperative complication rate was 68.1%, including 38.7% with multiple complications. The mortality rate was 1.9%. The number of women with multiple perioperative complications increased from 29.4% in 2001-2005 to 52.8% in 2011-2015 (78.6% relative increase, P < 0.001). More recent year of surgery, obesity, higher comorbidity, higher household income, surgery at large bedsize hospital, urinary diversion, vaginal reconstruction, and vulvar cancer were associated with an increased risk of multiple complications on multivariable analysis (all, P < 0.05). Median length of stay was 14 (IQR 9-21) days, and the number of women hospitalized ≥28 days significantly increased from 12.6% in 2001-2005 to 19.1% in 2011-2015 (51.6% relative increase, P < 0.001). The median corrected total charges increased from $121,854 to $185,100 between 2001 and 2015 (net difference +$63,246, 51.9% relative increase, P < 0.001). CONCLUSION: Women undergoing pelvic exenteration for gynecologic malignancies became more obese and comorbid during the study period. Pelvic exenteration for women with gynecologic malignancies is associated with high morbidity and mortality as well as substantial treatment-related costs.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Mandelbaum RS, Adams CL, et al. Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. Gynecol Oncol. 2019. PMID: 30792003. doi:10.1016/j.ygyno.2019.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。